About this condition
Ménière's Disease — Genetic Risk
Ménière's disease (endolymphatic hydrops) causes episodic vertigo, fluctuating sensorineural hearing loss, tinnitus, and aural fullness. It affects approximately 200 per 100,000. Familial Ménière's disease occurs in 8-11% of cases — typically autosomal dominant with variable penetrance. Candidate genes include DTNA (dystrobrevin alpha), FAM136A, and PRKCB.
HLA associations suggest autoimmune contribution — HLA-DRB1 alleles (particularly *11:01 in some populations) have been associated with Ménière's susceptibility. Autoimmune comorbidities (rheumatoid arthritis, psoriasis, lupus) are more common in Ménière's patients. These findings support immunomodulatory treatment approaches (intratympanic steroids, systemic steroids for acute flares).
Critically, several genetic hearing loss syndromes can mimic Ménière's: DFNA9 (COCH — progressive vestibulocochlear dysfunction), enlarged vestibular aqueduct (SLC26A4/Pendred), and mitochondrial mutations (MT-RNR1 aminoglycoside susceptibility, A1555G). Molecular genetic testing differentiates true Ménière's from these genetic mimics — which have different prognoses and management.
DFNA9 (COCH mutations) mimics Ménière's with progressive hearing loss and vestibular failure. If 'Ménière's' runs in your family, COCH testing is important — it's a different disease with different management.
- Gene locus
- DTNA (18q12.1), FAM136A (2p14), COCH (14q12), SLC26A4 (7q22.3), HLA-DRB1 (6p21.32)
